Leiutis Pharmaceuticals LLP

General

Total Cases3

Active Cases2

Patents7

CourtsD. Delaware D. New Jersey N.D. Illinois

TypeOperating Company

Elite Ratings

--

leiutis-pharmaceuticals

leiutis-pharmaceuticals

Ratings

Experience

Grade

Trend

DCT

--

--

--

PTAB

--

--

--

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
08/20/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	MINUTE entry before the Honorable Maria Valdez: This matter has been referred to Judge Valdez for discovery supervision and to conduct a settlement conference. The parties shall file a joint status report on discovery progress by 9/13/24. If they wish to begin the process of scheduling a settlement conference at any time prior to that date, they may notify the Court. Mailed notice (lp, ) (Entered: 08/20/2024) MINUTE entry before the Honorable Maria Valdez: This matter has been referred to Judge Valdez for discovery supervision and to conduct a settlement conference. The parties shall file a joint status report on discovery progress by 9/13/24. If they wish to begin the process of scheduling a settlement conference at any time prior to that date, they may notify the Court. Mailed notice (lp, ) (Entered: 08/20/2024)
08/19/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	TRANSCRIPT OF PROCEEDINGS held on 8/16/24 before the Honorable Mary M. Rowland. Video status. Order Number: 49589. Court Reporter Contact Information: Laura Renke, OfficialTranscript@gmail.com, 312.435.6053. IMPORTANT: The transcript may be viewed at the court's public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through the Court Reporter/Transcriber or PACER. For further information on the redaction process, see the Court's web site at www.ilnd.uscourts.gov under Quick Links select Policy Regarding the Availability of Transcripts of Court Proceedings. Redaction Request due 9/9/2024. Redacted Transcript Deadline set for 9/19/2024. Release of Transcript Restriction set for 11/18/2024. (Renke, Laura) (Entered: 08/19/2024) TRANSCRIPT OF PROCEEDINGS held on 8/16/24 before the Honorable Mary M. Rowland. Video status. Order Number: 49589. Court Reporter Contact Information: Laura Renke, OfficialTranscript@gmail.com, 312.435.6053. IMPORTANT: The transcript may be viewed at the court's public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through the Court Reporter/Transcriber or PACER. For further information on the redaction process, see the Court's web site at www.ilnd.uscourts.gov under Quick Links select Policy Regarding the Availability of Transcripts of Court Proceedings. Redaction Request due 9/9/2024. Redacted Transcript Deadline set for 9/19/2024. Release of Transcript Restriction set for 11/18/2024. (Renke, Laura) (Entered: 08/19/2024)
08/16/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	Pursuant to Local Rule 72.1, this case is hereby referred to the calendar of Honorable Maria Valdez for the purpose of holding proceedings related to: discovery supervision and settlement conference. (dm, )Mailed notice. (Entered: 08/16/2024)
08/16/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	MINUTE entry before the Honorable Mary M. Rowland: Hearing held on 8/16/24 on Webex. Counsel for Plaintiffs and Defendant appeared. Defendant may depose Dr. Adolph Bohnstedt but the deposition is limited to 3.5 hours. Plaintiffs' motion for a preliminary injunction due 9/16/24 and Plaintiffs shall identify declarants by 9/9/24. Defendant's response to Plaintiffs' motion due 10/11/24 and Defendant shall identify declarants by 10/7/24. If parties are unable to resolve the issue of standing, both parties should address the issue of standing in their briefs. On 10/16/24, Defendant shall file status report on whether it intends to commercially launch its generic cyclophosphamide products into the U.S. market on 10/21/24. In person preliminary injunction hearing set for 10/17/24 at 1:30 p.m. This matter is referred to the magistrate judge to supervise discovery and for any settlement discussions. The magistrate judge has full authority over the deadlines. Discovery required for the preliminary injunction has to be done on an expedited basis. Telephonic status hearing set for 9/19/24 at 9:30 a.m. The call-in number for the hearing is 866-434-5269; access code 3751971. Members of the public and media will be able to call in to listen to the hearing. Persons granted remote access to proceedings are reminded of the general prohibition against photographing, recording, and rebroadcasting of court proceedings. Violation of these prohibitions may result in sanctions, including removal of court issued media credentials, restricted entry to future hearings, denial of entry to future hearings, or any other sanctions deemed necessary by the Court. Mailed notice. (dm, ) (Entered: 08/16/2024) MINUTE entry before the Honorable Mary M. Rowland: Hearing held on 8/16/24 on Webex. Counsel for Plaintiffs and Defendant appeared. Defendant may depose Dr. Adolph Bohnstedt but the deposition is limited to 3.5 hours. Plaintiffs' motion for a preliminary injunction due 9/16/24 and Plaintiffs shall identify declarants by 9/9/24. Defendant's response to Plaintiffs' motion due 10/11/24 and Defendant shall identify declarants by 10/7/24. If parties are unable to resolve the issue of standing, both parties should address the issue of standing in their briefs. On 10/16/24, Defendant shall file status report on whether it intends to commercially launch its generic cyclophosphamide products into the U.S. market on 10/21/24. In person preliminary injunction hearing set for 10/17/24 at 1:30 p.m. This matter is referred to the magistrate judge to supervise discovery and for any settlement discussions. The magistrate judge has full authority over the deadlines. Discovery required for the preliminary injunction has to be done on an expedited basis. Telephonic status hearing set for 9/19/24 at 9:30 a.m. The call-in number for the hearing is 866-434-5269; access code 3751971. Members of the public and media will be able to call in to listen to the hearing. Persons granted remote access to proceedings are reminded of the general prohibition against photographing, recording, and rebroadcasting of court proceedings. Violation of these prohibitions may result in sanctions, including removal of court issued media credentials, restricted entry to future hearings, denial of entry to future hearings, or any other sanctions deemed necessary by the Court. Mailed notice. (dm, ) (Entered: 08/16/2024)
08/13/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	MINUTE entry before the Honorable Mary M. Rowland: The Court has reviewed the parties' joint status report 84 . The parties have proposed a discovery schedule for remaining fact discovery and expert discovery. The Court adopts the parties proposed dates. Claim Construction Ruling by July 31, 2024; Post-Claim Construction Fact Discovery (LPR 1.3) by September 11, 2024; Disclosure of Defendant's Opinions of Counsel N/A (Defendant will not rely on opinions of counsel) ; Initial Expert Disclosures (LPR 5.1(b)) from party with the burden of proof (including Plaintiff's objective indicia of nonobviousness) due October 9, 2024; Rebuttal Expert Disclosures (LPR 5.1(c)) due November 6, 2024; Reply Expert Disclosures due December 4, 2024; Completion of Expert Witness Depositions (LPR 5.2) on January 1, 2025. Status hearing to discuss other matters raised in the status report, including setting a settlement conference, set for 8/16/24 at 10:45 AM via Webex. Counsel of record will receive an email with a link to join the video conference prior to the hearing. Members of the public and media will be able to call in to listen to this hearing. The call-in number is 650-479-3207 and the call-in ID is 1801732451. Persons granted remote access to proceedings are reminded of the general prohibition against photographing, recording, and rebroadcasting of court proceedings. Violation of these prohibitions may result in sanctions, including removal of court issued media credentials, restricted entry to future hearings, denial of entry to future hearings, or any other sanctions deemed necessary by the Court. Mailed notice. (dm, ) (Entered: 08/13/2024) MINUTE entry before the Honorable Mary M. Rowland: The Court has reviewed the parties' joint status report 84 . The parties have proposed a discovery schedule for remaining fact discovery and expert discovery. The Court adopts the parties proposed dates. Claim Construction Ruling by July 31, 2024; Post-Claim Construction Fact Discovery (LPR 1.3) by September 11, 2024; Disclosure of Defendant's Opinions of Counsel N/A (Defendant will not rely on opinions of counsel) ; Initial Expert Disclosures (LPR 5.1(b)) from party with the burden of proof (including Plaintiff's objective indicia of nonobviousness) due October 9, 2024; Rebuttal Expert Disclosures (LPR 5.1(c)) due November 6, 2024; Reply Expert Disclosures due December 4, 2024; Completion of Expert Witness Depositions (LPR 5.2) on January 1, 2025. Status hearing to discuss other matters raised in the status report, including setting a settlement conference, set for 8/16/24 at 10:45 AM via Webex. Counsel of record will receive an email with a link to join the video conference prior to the hearing. Members of the public and media will be able to call in to listen to this hearing. The call-in number is 650-479-3207 and the call-in ID is 1801732451. Persons granted remote access to proceedings are reminded of the general prohibition against photographing, recording, and rebroadcasting of court proceedings. Violation of these prohibitions may result in sanctions, including removal of court issued media credentials, restricted entry to future hearings, denial of entry to future hearings, or any other sanctions deemed necessary by the Court. Mailed notice. (dm, ) (Entered: 08/13/2024)
08/12/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	JOINT STATUS REPORT by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) (Entered: 08/12/2024)
08/12/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	JOINT STATUS REPORT by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) (Entered: 08/12/2024)
07/31/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	MEMORANDUM Opinion and Order: For the reasons stated in the Memorandum Opinion and Order, the Court adopts the constructions identified, defers consideration of the claim term Defendant asserts is indefinite, and grants Plaintiffs' motion for judgment on the pleadings 43 . Defendant's counterclaim is dismissed with prejudice. Court staff is in receipt of emails from Plaintiff's counsel that contains substantive information. Emails are not part of the court record. On or before 8/12/24, parties are to file a joint status report indicating (a) dates for remaining discovery, (b) status of the subpoena ad testificandum at issue in 23 C 2871, (c) whether a settlement conference would be productive, and (d) any other issues they would like to raise with the court. Signed by the Honorable Mary M. Rowland on 7/31/2024. (See attached Order for further detail.) Mailed notice. (dm, ) (Entered: 07/31/2024) MEMORANDUM Opinion and Order: For the reasons stated in the Memorandum Opinion and Order, the Court adopts the constructions identified, defers consideration of the claim term Defendant asserts is indefinite, and grants Plaintiffs' motion for judgment on the pleadings 43 . Defendant's counterclaim is dismissed with prejudice. Court staff is in receipt of emails from Plaintiff's counsel that contains substantive information. Emails are not part of the court record. On or before 8/12/24, parties are to file a joint status report indicating (a) dates for remaining discovery, (b) status of the subpoena ad testificandum at issue in 23 C 2871, (c) whether a settlement conference would be productive, and (d) any other issues they would like to raise with the court. Signed by the Honorable Mary M. Rowland on 7/31/2024. (See attached Order for further detail.) Mailed notice. (dm, ) (Entered: 07/31/2024)
04/19/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	EXECUTIVE COMMITTEE ORDER: Case reassigned to the Honorable Mary M. Rowland for all further proceedings pursuant to Internal Operating Procedure 13(d). Honorable Sunil R. Harjani no longer assigned to the case. Signed by Executive Committee on 4/19/2024. (ph, ) (Entered: 04/19/2024)
04/02/24	Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc 1:22-CV-02868 ( N.D. IL )	EXECUTIVE COMMITTEE ORDER: GENERAL ORDER 24-0008: IT APPEARING THAT, the civil cases on the attached list have been selected for reassignment to form the initial calendar of the Honorable Sunil R. Harjani; therefore IT IS HEREBY ORDERED that the attached list of 290 cases be reassigned to the Honorable Sunil R. Harjani; and IT IS FURTHER ORDERED that all parties affected by this Order must review the Honorable Sunil R. Harjani's webpage on the Court's website for the purpose of reviewing instructions regarding scheduling and case management procedures; and IT IS FURTHER ORDERED that any civil case that has been reassigned pursuant to this Order will not be randomly reassigned to create the initial calendar of a new district judge for twelve months from the date of this Order; and IT IS FURTHER ORDERED that the Clerk of Court is directed to add the Honorable Sunil R. Harjani to the Court's civil case assignment system during the next business day, so that he shall receive a full share of such cases; and IT IS FURTHER ORDERED that the Clerk of Court is directed to add the Honorable Sunil R. Harjani to the Court's criminal case assignment system ninety (90) days so that Judge Harjani shall thereafter receive a full share of such cases. Case reassigned to the Honorable Sunil R. Harjani for all further proceedings. Honorable Mary M. Rowland no longer assigned to the case. Signed by Honorable Rebecca R. Pallmeyer on 4/02/2024.(tg, ) (Entered: 04/02/2024) EXECUTIVE COMMITTEE ORDER: GENERAL ORDER 24-0008: IT APPEARING THAT, the civil cases on the attached list have been selected for reassignment to form the initial calendar of the Honorable Sunil R. Harjani; therefore IT IS HEREBY ORDERED that the attached list of 290 cases be reassigned to the Honorable Sunil R. Harjani; and IT IS FURTHER ORDERED that all parties affected by this Order must review the Honorable Sunil R. Harjani's webpage on the Court's website for the purpose of reviewing instructions regarding scheduling and case management procedures; and IT IS FURTHER ORDERED that any civil case that has been reassigned pursuant to this Order will not be randomly reassigned to create the initial calendar of a new district judge for twelve months from the date of this Order; and IT IS FURTHER ORDERED that the Clerk of Court is directed to add the Honorable Sunil R. Harjani to the Court's civil case assignment system during the next business day, so that he shall receive a full share of such cases; and IT IS FURTHER ORDERED that the Clerk of Court is directed to add the Honorable Sunil R. Harjani to the Court's criminal case assignment system ninety (90) days so that Judge Harjani shall thereafter receive a full share of such cases. Case reassigned to the Honorable Sunil R. Harjani for all further proceedings. Honorable Mary M. Rowland no longer assigned to the case. Signed by Honorable Rebecca R. Pallmeyer on 4/02/2024.(tg, ) (Entered: 04/02/2024)